Morgan Stanley Downgrades Novo Nordisk to Sell on Lilly Competition
Novo Nordisk A/S (NVO, Financials), the Danish drugmaker behind Wegovy and Ozempic, is facing a problem that may arrive well before its patent cliff.Morgan Stanley downgraded the stock to Sell after its latest survey suggested Eli Lilly could keep taking share in the fast-growing obesity and diabet…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.